Conflict of Interest Disclosures: Dr Vart reported receiving grants from AstraZeneca during the conduct of the study. Dr Wheeler reported receiving personal fees from AstraZeneca during the conduct of the study; personal fees from Astellas, Boehringer Ingelheim, Bayer, GlaxoSmithKline, Janssen, Gilead, Merck Sharp and Dohme, George Clinical, Intas, ProKidney, Tricida, Vifor, and Zydus outside the submitted work; and performing guideline development for KDIGO. Dr Heerspink reported receiving research support from and serving as a consultant for AstraZeneca during the conduct of the study; serving as a consultant for Bayer, Chinook Tx, CSL Behring, Dimerix, Eli Lilly, Fresenius, Gilead, Novartis, and Travere Therapeutics outside the submitted work; receiving grants and research support from Boehringer Ingelheim and Janssen outside the submitted work; and receiving grants from and serving as a consultant for NovoNordisk outside the submitted work. Dr Langkilde reported being a full-time employee and shareholder of AstraZeneca during the conduct of the study. Dr Chertow reported receiving personal fees from AstraZeneca during the conduct of the study; receiving personal fees from Akebia, Ardelyx, Gilead, Reata, Sanifit, Vertex, and Satellite Healthcare outside the submitted work; serving on the advisory board for and holding stock options in CloudCath, Durect, Miromatrix, Outset, and Univycive outside the submitted work; and receiving grants to institution from CSL Behring Steering Committee outside the submitted work. No other disclosures were reported.